GLP-1 as a Satiety Factor in Children with Eating Disorders

Abstract

GLP-1, with its insulinotropic properties and direct action on satiety center in the brain, may be the main hormone regulating the amount of ingested food. In this study, GLP-1 secretion was investigated in age-matched adolescent girls (14 ± 2 years): 13 with anorexia nervosa (BMI 14.8 ± 1.4 kg/m²), 13 with simple obesity (BMI 33.0 ± 3.3 kg/m²) and 10 healthy girls as a control group (BMI 21.6 ± 0.7 kg/m²). Each girl was subjected to OGTT and standard meal tests after a 12 h overnight fast. Blood samples were collected before and 15, 30, 60, and 120 min after the stimulation. The mean fasted GLP-1 levels in simple obesity group (1.6 ± 0.3 pmol/l) and in anorexia nervosa group (1.7 ± 0.3 pmol/l) were significantly lower than those in the control group (2.6 ± 0.4 pmol/l) (p < 0.05 in both cases). The highest peak concentration of GLP-1 was observed in the control group after both stimuli. In each group, the mean integrated GLP-1 outputs were almost twice as high after OGTT than after the test meal (p < 0.001 in each case). In our opinion, low secretion of GLP-1 in girls with simple obesity may seriously and negatively influence the course of this disease. On the other hand, low GLP-1 levels in girls with anorexia nervosa are beneficial and promote appetite.

Simple Obesity - Anorexia Nervosa - Appetite

References

• 1 Orskov C, Holst J J, Poulsen S S, Kirkegaard P. Pancreatic and intestinal processing of proglucagon in man.  Diabetologia. 1987;  30 874-881
• 2 Manaka H, Sugiyama K, Takahashi H. tGLP-1 release from isolated perfused canine ileum.  Digestion. 1990;  46 suppl 1 66
• 3 Fehmann H C, Bode H P, Ebert T, Karl A, Goke B. Interaction of GLP-I and leptin at rat pancreatic B-cells: effects on insulin secretion and signal transduction.  Horm Metab Res. 1997;  29 572-576
• 4 Fehmann H C, Goke R, Goke B. Cell and molecular biology of the incretin hormones, glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.  Endocrine Reviews. 1995;  15 390-407
• 5 Kreymann B, Williams M, Ghatei M, Bloom S. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet II 1987: 1300-1303
• 6 Holst J J. Glucagonlike Peptide 1: A newly discovered gastrointestinal hormone.  Gastroenterology. 1994;  107 1848-1855
• 7 Tang-Christensen M, Larsen P J, Goke R, Fink-Jensen A, Jessop D S, Molker M, Sheikh S P. Central administration of GLP-1 (7-36) amide inhibits food and water intake in rats.  Am J Physiol. 1996;  271 R848-R856
• 8 Turton M D, O'Shea D, Gunn I, Beak S A, Edwards C M, Meeran K, Choi S J, Taylor G M, Heath M M, Lambert P D, Wilding J P, Smith D M, Ghatei M A, Herbert J, Bloom S R. A role for glucagon-like peptide 1 in the central regulation of feeding.  Nature. 1996;  379 69-72
• 9 Hassan M, Eskilsson A, Nilsson C, Jonsson C, Jackobsson H, Refai E, Larsson S, Effendic S. In vivo dynamic distribution of ¹³¹I-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera.  Nucl Med Biol. 1999;  26 413-420
• 10 Flint A, Raben A, Astrup A, Holst J J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.  J Clin Invest. 1998;  101 515-520
• 11 Naslund E, Gutniak M, Skogar S, Rosner S, Hellstrom P M. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese man.  Am J Clin Nutr. 1998;  68 525-530
• 12 Gutzwiller J P, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C. Glucagon-like peptide 1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.  Am J Physiol. 1999;  276 R1541-R1544
• 13 Toft-Nielsen M B, Madsbad S, Holst J J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.  Diabetes Care. 1999;  22 1137-1143
• 14 Lavin J H, Wittert G A, Andrews J, Jeap B, Wishart J M, Morris H A, Morley J E, Horowitz M, Read N W. Interaction of insulin, glucagon-like peptide 1, gastric inhibitory polypeptide, and appetite in response to intraduodenal carbohydrate.  Am J Clin Nutr. 1998;  68 591-598
• 15 Halmi K A. Pragmatic information on the eating disorders.  Psychiatr Clin North Am. 1982;  5 371-377
• 16 Miholic J, Orskov C, Holst J J, Kotzerke J, Meyer H J. Emptying of the gastric substitute, glucagon-like peptide 1 (GLP-1), and reactive hypoglycemia after total gastrectomy.  Dig Dis Sci. 1991;  36 1361-1370
• 17 Holst J J. Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2.  Reg Pep. 2000;  93 45-51
• 18 Ranganath L, Beety J, Morgan L, Wright J W, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence.  Gut. 1996;  38 916-919
• 19 Ranganath L, Norris F, Morgan L, Wright J, Marks V. Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36) amide secretion by circulating non-esterified fatty acids.  Clin Sci Colch. 1999;  96 335-342
• 20 Basilisco G, Camboni G, Bozzani A, Vita P, Doldi S, Bianchi P A. Orocecal transit delay in obese patients.  Dig Dis Sci. 1989;  34 509-512
• 21 Wilmshurst P, Crawley JC. The measurement of gastric transit time in obese subjects using ²⁴Na and the effects of energy content and guar gum on gastric emptying and satiety.  Br J Nutr. 1980;  44 1-6
• 22 Lugari R, Dell’Anna C, Ugolotti D, DeiCas A, Barilli A L, Zandomeneghi R, Marani B, Iotti M, Orlandini A, Gnudi A. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.  Horm Metab Res. 2000;  32 424-428
• 23 Seeley R J, Blake K, Rushing P A, Benoit S, Eng J, Woods S C, D'Alessio D. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride.  J Neurosci. 2000;  20 1616-1621
• 24 Rinaman L. A functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia.  Am J Physiol. 1999;  277 R1537-R1540